{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:21:04Z","timestamp":1769584864539,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11864-021-00816-5","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T14:03:07Z","timestamp":1614348187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Insights into the Use of Peripherally Acting \u03bc-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice"],"prefix":"10.1007","volume":"22","author":[{"given":"Ana","family":"Fern\u00e1ndez-Montes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Agu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Farriols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Guirado-Risue\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa G.","family":"Jerviz-Gu\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Baeza-Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Chicas-Sett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"F\u00edrvida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Garc\u00eda-Naval\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Perezagua-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Saur\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"3","key":"816_CR1","doi-asserted-by":"publisher","first-page":"G501","DOI":"10.1152\/ajpgi.00442.2015","volume":"311","author":"PA Hughes","year":"2016","unstructured":"Hughes PA, et al. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501\u201313.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"816_CR2","first-page":"5","volume":"6","author":"Z Azizi","year":"2014","unstructured":"Azizi Z, Javid Anbardan S, Ebrahimi Daryani N. A review of the clinical manifestations, pathophysiology and management of opioid bowel dysfunction and narcotic bowel syndrome. Middle East J Dig Dis. 2014;6(1):5\u201312.","journal-title":"Middle East J Dig Dis"},{"issue":"Suppl 4","key":"816_CR3","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","volume":"29","author":"PJ Larkin","year":"2018","unstructured":"\u2022\u2022 Larkin PJ, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv111\u201325 ESMO Clinical Practice Guidelines that highlights the impact of constipation and discuss pharmacological and non-pharmacological options for management, as well as the challenges of treatments in older cancer patients at enhanced risk of constipation.","journal-title":"Ann Oncol"},{"issue":"1","key":"816_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","volume":"7","author":"AD Farmer","year":"2019","unstructured":"\u2022\u2022 Farmer AD, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019;7(1):7\u201320 An European expert panel evaluates current evidence in the literature regarding pathophysiology and clinical evaluation of OIC, the importance of early OIC recognition and the need of combined therapies as well as provides a management algorithm for day-to-day clinical practice.","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"816_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35\u201342.","journal-title":"Pain Med"},{"key":"816_CR6","doi-asserted-by":"publisher","unstructured":"Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;S0016-5085(16):00223\u20137. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.032.","DOI":"10.1053\/j.gastro.2016.02.032"},{"issue":"6","key":"816_CR7","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257\u201361.","journal-title":"Gastroenterology"},{"key":"816_CR8","doi-asserted-by":"publisher","unstructured":"Mearin F, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16):00222\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.031.","DOI":"10.1053\/j.gastro.2016.02.031"},{"issue":"1","key":"816_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/j.gastro.2018.10.044","volume":"156","author":"S Crockett","year":"2019","unstructured":"Crockett S, Greer KB, Sultan S. Opioid-induced constipation (OIC) Guideline. Gastroenterology. 2019;156(1):228.","journal-title":"Gastroenterology"},{"issue":"1","key":"816_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00520-019-05016-4","volume":"28","author":"A Davies","year":"2020","unstructured":"\u2022 Davies A, et al. MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer. 2020;28(1):23\u201333 The Palliative Care Study Group of the MASCC provide 15 recommendations with varying guideline categories for assessment, treatment and re-assessment of constipation in advanced cancer, with varying levels of evidence.","journal-title":"Support Care Cancer"},{"key":"816_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.sjpain.2015.12.007","volume":"11","author":"HN Christensen","year":"2016","unstructured":"Christensen HN, et al. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain. 2016;11:104\u201310.","journal-title":"Scand J Pain"},{"issue":"10","key":"816_CR12","first-page":"1932","volume":"18","author":"A Emmanuel","year":"2017","unstructured":"Emmanuel A, et al. Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pain Med. 2017;18(10):1932\u201340.","journal-title":"Pain Med"},{"issue":"12","key":"816_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/ijcp.12718","volume":"69","author":"RJ LoCasale","year":"2015","unstructured":"LoCasale RJ, et al. The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use. Int J Clin Pract. 2015;69(12):1448\u201356.","journal-title":"Int J Clin Pract"},{"key":"816_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijcard.2016.03.079","volume":"212","author":"A Sandhu","year":"2016","unstructured":"Sandhu A, et al. Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. Int J Cardiol. 2016;212:360\u20133.","journal-title":"Int J Cardiol"},{"issue":"3","key":"816_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00520-014-2435-5","volume":"23","author":"SH Ahmedzai","year":"2015","unstructured":"Ahmedzai SH, et al. Long-term safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015;23(3):823\u201330.","journal-title":"Support Care Cancer"},{"issue":"4","key":"816_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/13543784.2011.563236","volume":"20","author":"K Smith","year":"2011","unstructured":"Smith K, et al. Naloxone as part of a prolonged release oxycodone\/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20(4):427\u201339.","journal-title":"Expert Opin Investig Drugs"},{"key":"816_CR17","doi-asserted-by":"publisher","first-page":"141737","DOI":"10.1155\/2014\/141737","volume":"2014","author":"L Kumar","year":"2014","unstructured":"Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:141737.","journal-title":"Gastroenterol Res Pract"},{"key":"816_CR18","doi-asserted-by":"publisher","unstructured":"Luthra P, et al. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut. 2019;68(3):434\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2018-316001.","DOI":"10.1136\/gutjnl-2018-316001"},{"issue":"5","key":"816_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/jgh.14586","volume":"34","author":"K Nishie","year":"2019","unstructured":"\u2022\u2022 Nishie K, et al. Peripherally acting mu-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34(5):818\u201329 Systematic review of the efficacy of PAMORAs in patients with opioid-induced constipation.","journal-title":"J Gastroenterol Hepatol"},{"issue":"25","key":"816_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"816_CR21","first-page":"37","volume":"27","author":"A Libran Oriol","year":"2020","unstructured":"Libran Oriol A, et al. Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review. Rev Soc Esp Dolor. 2020;27(1):37\u201349.","journal-title":"Rev Soc Esp Dolor"},{"issue":"10","key":"816_CR22","first-page":"574","volume":"33","author":"GI Erowele","year":"2008","unstructured":"Erowele GI. Alvimopan (Entereg), a Peripherally acting mu-opioid receptor antagonist for postoperative Ileus. P T. 2008;33(10):574\u201383.","journal-title":"P T"},{"issue":"5A Suppl","key":"816_CR23","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1016\/S0002-9610(01)00784-X","volume":"182","author":"WK Schmidt","year":"2001","unstructured":"Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182(5A Suppl):27S\u201338S.","journal-title":"Am J Surg"},{"issue":"2","key":"816_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.pain.2007.11.008","volume":"137","author":"L Webster","year":"2008","unstructured":"Webster L, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137(2):428\u201340.","journal-title":"Pain"},{"issue":"5","key":"816_CR25","doi-asserted-by":"publisher","first-page":"e13250","DOI":"10.1111\/nmo.13250","volume":"30","author":"K van Malderen","year":"2018","unstructured":"\u2022 van Malderen K, Halawi H, Camilleri M. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naive patients. Neurogastroenterol Motil. 2018;30(5):e13250 This review evaluates the efficacious doses of PAMORAs for opioid-na\u00efve or chronic opioid users.","journal-title":"Neurogastroenterol Motil"},{"issue":"34","key":"816_CR26","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859\u201366.","journal-title":"J Clin Oncol"},{"issue":"17","key":"816_CR27","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, et al. Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol. 2017;35(17):1921\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"816_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0018578717724805","volume":"52","author":"DE Baker","year":"2017","unstructured":"Baker DE. Formulary drug review: naldemedine. Hosp Pharm. 2017;52(7):464\u20138.","journal-title":"Hosp Pharm"},{"issue":"8","key":"816_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-017-0750-0","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Naldemedine: first global approval. Drugs. 2017;77(8):923\u20137.","journal-title":"Drugs"},{"key":"816_CR30","doi-asserted-by":"publisher","unstructured":"Kanemasa T, et al. Profile of Naldemedine, a Peripherally Acting \u03bc-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol. J Pharmacol Exp Ther. 2020;373(3):438\u201344. https:\/\/doi.org\/10.1124\/jpet.119.264515.","DOI":"10.1124\/jpet.119.264515"},{"issue":"7","key":"816_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/apt.12899","volume":"40","author":"L Webster","year":"2014","unstructured":"Webster L, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"816_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/2050640615604543","volume":"3","author":"J Tack","year":"2015","unstructured":"Tack J, et al. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015;3(5):471\u201380.","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"816_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5055\/jom.2016.0360","volume":"12","author":"L Webster","year":"2016","unstructured":"Webster L, et al. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation. J Opioid Manag. 2016;12(6):405\u201319.","journal-title":"J Opioid Manag"},{"issue":"4","key":"816_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40265-015-0357-2","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015;75(4):419\u201325.","journal-title":"Drugs"},{"key":"816_CR35","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Dols MC, et al. Analysis of the efficacy and safety of naloxegol administered to patients with cancer and opioid-induced constipation with laxative-inadequate response: a real-world 12\u00a0months of follow-up study. J Clin Oncol. 2020;38(15_suppl):e24155\u20135 This real-world-data study confirms long-term efficacy, safety and tolerability of naloxegol in cancer patients with OIC maintaining pain control.","DOI":"10.1200\/JCO.2020.38.15_suppl.e24155"},{"key":"816_CR36","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Davies A, et al. Naloxegol for patients with cancer pain diagnosed with opioid induced constipation (OIC): NACASY observational study. J Clin Oncol. 2020;38:e19350\u20130 This real-world study evaluates safety and efficacy of naloxegol in patients with cancer pain diagnosed with OIC.","DOI":"10.1200\/JCO.2020.38.15_suppl.e19350"},{"issue":"12","key":"816_CR37","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.clinthera.2013.09.019","volume":"35","author":"C Gottfridsson","year":"2013","unstructured":"Gottfridsson C, et al. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT\/QTc study in healthy volunteers. Clin Ther. 2013;35(12):1876\u201383.","journal-title":"Clin Ther"},{"issue":"6","key":"816_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cpdd.206","volume":"4","author":"MA Eldon","year":"2015","unstructured":"Eldon MA, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: a single ascending-dose study. Clin Pharmacol Drug Dev. 2015;4(6):434\u201341.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"816_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/1074248418760239","volume":"23","author":"WB White","year":"2018","unstructured":"White WB, et al. Cardiovascular safety of the selective mu-opioid receptor antagonist naloxegol: a novel therapy for opioid-induced constipation. J Cardiovasc Pharmacol Ther. 2018;23(4):309\u201317.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"816_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bcp.12756","volume":"81","author":"N Al-Huniti","year":"2016","unstructured":"Al-Huniti N, et al. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol. 2016;81(1):89\u2013100.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"816_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/jcpt.12812","volume":"44","author":"RB Raffa","year":"2019","unstructured":"\u2022\u2022 Raffa RB, Taylor R Jr, Pergolizzi JV Jr. Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. J Clin Pharm Ther. 2019;44(3):361\u201371 This article reviews the potential for metabolic drug interactions of PAMORAs with other medications in patients treated for OIC and other comorbidities.","journal-title":"J Clin Pharm Ther"},{"key":"816_CR42","unstructured":"Moventing\u00ae(naloxegol), Full prescribing information. 2019 (last update), Bloemlaan 2, 2132NP Hoofddorp, The Netherlands: Kyowa Kirin Holdings B.V. [Last access January 28]: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/moventig-epar-product-information_en.pdf."},{"key":"816_CR43","unstructured":"Rizmoic\u00ae(naldemedine), Full prescribing information. 2020 (last update), Kingsfordweg 151, 1043GR Amsterdan, The Netherlands: Shionogi B.V. [Last access January 28]: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/rizmoic-epar-product-information_en.pdf"},{"issue":"Suppl 4","key":"816_CR44","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"M Fallon","year":"2018","unstructured":"\u2022\u2022 Fallon M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166\u201391 ESMO Clinical Practice Guidelines that recommends the use of laxatives for prevention and treatment of opioid-induced intestinal dysfunctions in oncological patients.","journal-title":"Ann Oncol"},{"key":"816_CR45","unstructured":"Relistor\u00ae(methylnaltrexone), Full prescribing information. 2019 (last update), Jankovcova 1569\/2c,Lighthouse 17,000 Prague 7, Czech Republic: PharmaSwiss Ceska Republika s.r.o. [Last access January 28]: https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/relistor-epar-product-information_en.pdf."},{"issue":"2","key":"816_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5056\/jnm16214","volume":"23","author":"MJ Schmulson","year":"2017","unstructured":"Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151\u201363.","journal-title":"J Neurogastroenterol Motil"},{"issue":"10","key":"816_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11894-014-0410-4","volume":"16","author":"E Szigethy","year":"2014","unstructured":"Szigethy E, Schwartz M, Drossman D. Narcotic bowel syndrome and opioid-induced constipation. Curr Gastroenterol Rep. 2014;16(10):410.","journal-title":"Curr Gastroenterol Rep"},{"issue":"10","key":"816_CR48","first-page":"1837","volume":"18","author":"S Muller-Lissner","year":"2017","unstructured":"Muller-Lissner S, et al. Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. Pain Med. 2017;18(10):1837\u201363.","journal-title":"Pain Med"},{"issue":"8","key":"816_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1445-5994.2012.02726.x","volume":"42","author":"PR Gibson","year":"2012","unstructured":"Gibson PR, Morrison G. Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. Intern Med J. 2012;42(8):907\u201312.","journal-title":"Intern Med J"},{"issue":"7","key":"816_CR50","first-page":"410","volume":"11","author":"JE Kurlander","year":"2014","unstructured":"Kurlander JE, Drossman DA. diagnosis and treatment of narcotic bowel syndrome. Nat Rev. Gastroenterol Hepatol. 2014;11(7):410\u20138.","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"816_CR51","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jcph.348","volume":"54","author":"K Bui","year":"2014","unstructured":"Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54(12):1368\u201374.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"816_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1517\/17425255.2011.549824","volume":"7","author":"Y Rotshteyn","year":"2011","unstructured":"Rotshteyn Y, Boyd TA, Yuan CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol. 2011;7(2):227\u201335.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"816_CR53","doi-asserted-by":"publisher","unstructured":"Fukumura K, et al. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. Clin Pharmacol Drug Dev. 2020;9(2):162\u201374. https:\/\/doi.org\/10.1002\/cpdd.690.","DOI":"10.1002\/cpdd.690"},{"key":"816_CR54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/JPR.S237833","volume":"13","author":"LR Webster","year":"2020","unstructured":"Webster LR, et al. A renal impairment subgroup analysis of the safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy. J Pain Res. 2020;13:605\u201312.","journal-title":"J Pain Res"},{"key":"816_CR55","doi-asserted-by":"crossref","unstructured":"Streicher JM, Bilsky EJ. Peripherally acting micro-opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. J Pharm Pract. 2017:897190017732263.","DOI":"10.1177\/0897190017732263"},{"key":"816_CR56","doi-asserted-by":"publisher","unstructured":"Osaka I, et al. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. ESMO Open. 2019;4(4):e000527. https:\/\/doi.org\/10.1136\/esmoopen-2019-000527.","DOI":"10.1136\/esmoopen-2019-000527"},{"issue":"7","key":"816_CR57","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/jpm.2014.0362","volume":"18","author":"J Bull","year":"2015","unstructured":"Bull J, et al. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593\u2013600.","journal-title":"J Palliat Med"},{"issue":"22","key":"816_CR58","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"J Thomas","year":"2008","unstructured":"Thomas J, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332\u201343.","journal-title":"N Engl J Med"},{"key":"816_CR59","doi-asserted-by":"publisher","unstructured":"Cobo Dols M, et al. Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxativeinadequate response. Poster presented at: EFIC Congress 2019. Pain in Europe XI; September 4, 2019; Valencia, Spain. https:\/\/doi.org\/10.26226\/morressier.5d402fa18f2158d25ec13161.","DOI":"10.26226\/morressier.5d402fa18f2158d25ec13161"},{"key":"816_CR60","doi-asserted-by":"publisher","unstructured":"Webster LR, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebocontrolled phase 3 study. Pain. 2018;159(5):987\u201394. https:\/\/doi.org\/10.1097\/j.pain.0000000000001174.","DOI":"10.1097\/j.pain.0000000000001174"},{"key":"816_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/CIA.S8100","volume":"5","author":"SS Rao","year":"2010","unstructured":"Rao SS, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging. 2010;5:163\u201371.","journal-title":"Clin Interv Aging"},{"issue":"Suppl 11","key":"816_CR62","first-page":"S293","volume":"17","author":"T Lynch","year":"2011","unstructured":"Lynch T. Management of drug-drug interactions: considerations for special populations--focus on opioid use in the elderly and long term care. Am J Manag Care. 2011;17(Suppl 11):S293\u20138.","journal-title":"Am J Manag Care"},{"issue":"3","key":"816_CR63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4140\/TCP.n.2013.150","volume":"28","author":"CM Martin","year":"2013","unstructured":"Martin CM, Forrester CS. Anticipating and managing opioid side effects in the elderly. Consult Pharm. 2013;28(3):150\u20139.","journal-title":"Consult Pharm"},{"issue":"6","key":"816_CR64","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40262-016-0479-z","volume":"56","author":"K Bui","year":"2017","unstructured":"\u2022 Bui K, et al. Clinical pharmacokinetics and pharmacodynamics of naloxegol, a peripherally acting micro-opioid receptor antagonist. Clin Pharmacokinet. 2017;56(6):573\u201382 This article describes the pharmacokinetic\/dynamic properties of naloxegol.","journal-title":"Clin Pharmacokinet"},{"key":"816_CR65","doi-asserted-by":"publisher","unstructured":"Wild J, et al. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients \u2265 65 Years of Age. Drugs Aging. 2020;37(4):271\u20139. https:\/\/doi.org\/10.1007\/s40266-020-00753-2.","DOI":"10.1007\/s40266-020-00753-2"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T16:33:41Z","timestamp":1675010021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00816-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"11 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethic Standards"}},{"value":"All authors have received compensation from Kyowa Kirin Farmac\u00e9utica S.L.U. for service as consultants. Ana Fern\u00e1ndez-Montes has received grants from Kyowa Kirin outside the submitted work. Jos\u00e9 Luis-F\u00edrvida has received compensation from Astra Zeneca, Bristol-Myers Squibb, Lilly, Roche, and Takeda for service as consultant, not related to the submitted work. Guillermo de Velasco has received grants\/ personal fees from Pfizer, Roche, Ipsen, Astellas, Bayer, Bristol-Myers Squibb, Novartis, Janssen, Merck Sharp & Dohme, and Merck, outside the submitted work. Santiago Agu\u00edn has received personal personal fees from Merck, Merck Sharp & Dohme, and Bristol-Myers Squibb, outside the submitted work. Jos\u00e9 Luis F\u00edrvida has received compensation from Astra Zeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Roche, and Takeda for service as consultant, not related to the submitted work. Mar\u00eda Guirado-Risue\u00f1o has received personal fees and non-financial support from Kyowa Kirin and Roche and personal fees from Merck Sharp & Dohme, Bristol-Myers Squibb, and Astra Zeneca, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"26"}}